Medco Research's Adenocard (adenosine)
Medco Research's Adenocard (adenosine): Has received "approvable" status from FDA, the company announced Oct. 26, adding that it hopes to receive final approval in November. The injectable anti-arrhythmic product would be approved for I.V. treatment of paroxysmal supraventricular tachycardia in a hospital setting. Medco has licensed the drug to Fujisawa (Lyphomed) for marketing in the U.S. and to Sanofi for marketing outside North America. The drug was recommended for approval by FDA's Cardio-Renal Drugs Advisory Committee on May 4 ("The Pink Sheet" May 8, p. 7). The company is developing the drug for at least seven other indications.
You may also be interested in...
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.